Polysaccharide-silica nanocarriers for multimodal detection and anti-apoptotic therapy in hypertensive heart disease

Hypertensive heart disease (HHD) arises from chronic hypertension--induced cardiac remodeling (characterized by concentric hypertrophy, fibrosis, and diastolic dysfunction) and is driven, in part, by Ang II--mediated cardiomyocyte apoptosis, oxidative stress, and fibrotic signaling. To address this, we engineered a 1-DASA-ATPMS@CP1@Eth nanocomposite, synthesized by conjugating compound
1
to DASA and grafting onto 3-Aminopropyltrimethoxysilane (ATPMS) to form ∼200 nm spheres, then encapsulating CP1 (85% loading) and adsorbing ethoxysanguinarine (Eth). In Ang II–treated H9c2 cells, Eth-loaded nanoparticles (Eth-NPs) significantly preserved cell viability (CCK-8 assay) and down-regulated pro-apoptotic Bax mRNA (qPCR) compared to free Eth or blank nanoparticles. These findings indicate that the nanoparticle delivery system amplifies Eth’s anti-apoptotic efficacy and offers a promising strategy for targeting cardiomyocyte apoptosis in HHD treatment.